Kuno Wuersch, DVM, DECVP, has graduated from Veterinary School at the University of Berne in 2002, where he also wrote his doctoral thesis and completed his residency training in Veterinary Pathology. In 2007, he successfully passed his board exams and became a Diplomate of the ECVP.
After working as a toxicopathologist and part-time project team lead for Baxter in Vienna, he moved to Novartis in 2011 where he worked as pathologist and project team lead and since 2023 as a full-time toxicologist in the oncology disease area. During his tenure in the pharmaceutical industry, Kuno developed a special interest in oncology and large molecules and was part of many related projects including several antibody drug conjugate (ADC) programs, one of which has recently entered Ph1/2 clinical trials. He has also given industry-related lectures and has published on this topic including the current chapter on ADCs in the 2nd volume of “Current topics of nonclinical drug development, which is due to be released later this year. For Kuno, ADCs offer a challenging yet fascinating platform to address some of the currently underserved malignancies and might be more broadly applied in the future.